Evasin-4, a tick-derived chemokine-binding protein with broad selectivity can be modified for use in preclinical disease models

FEBS Journal

Volumn 280, Issue 19, 2013, Pages 4876-4887

  Déruaz, Maud ^a   Bonvin, Pauline ^a,b   Severin, India C ^a   Johnson, Zoë ^a   Krohn, Sonja ^a   Power, Christine A ^a   Proudfoot, Amanda E I ^a  

^a MERCK SERONO S A   (Switzerland)

^b NOVIMMUNE SA   (Switzerland)

Author keywords

anti inflammatory; binding protein; Fc fusion; hemokine; tick

Indexed keywords

ANALGESIC, ANTIINFLAMMATORY, ANTIRHEUMATIC AND ANTIGOUT AGENTS; ANTIINFLAMMATORY AGENT; BETA CHEMOKINE; CCL1 CHEMOKINE; CCL14 CHEMOKINE; CCL15 CHEMOKINE; CCL16 CHEMOKINE; CCL18 CHEMOKINE; CCL23 CHEMOKINE; CCL25 CHEMOKINE; CHEMOKINE; EOTAXIN; EVASIN 4; EVASIN 4 IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT EVASIN 4; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 4; RANTES; RECOMBINANT PROTEIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG; UROKINASE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MECHANISM; DRUG SELECTIVITY; FEMALE; GEL PERMEATION CHROMATOGRAPHY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; SURFACE PLASMON RESONANCE;

ANTI-INFLAMMATORY; BINDING PROTEIN; FC FUSION; HEMOKINE; TICK;

ANIMALS; CARRIER PROTEINS; CELL LINE; CHEMOKINE CCL2; CHEMOKINES, CC; HUMANS; MONOCYTE CHEMOATTRACTANT PROTEINS; PROTEIN BINDING; RECEPTORS, CHEMOKINE; TICKS;

IXODIDA; RHIPICEPHALUS SANGUINEUS;

EID: 84884591371     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12463     Document Type: Article

References (27)

1. Fallon PG, &, Alcami A, (2006) Pathogen-derived immunomodulatory molecules: future immunotherapeutics? Trends Immunol 27, 470-476.
2. Singh UP, Singh S, Ravichandran P, Taub DD, &, Lillard JW Jr, (2004) Viral macrophage-inflammatory protein-II: a viral chemokine that differentially affects adaptive mucosal immunity compared with its mammalian counterparts. J Immunol 173, 5509-5516.
3. Kuhn DE, Beall CJ, &, Kolattukudy PE, (1995) The cytomegalovirus US28 protein binds multiple CC chemokines with high affinity. Biochem Biophys Res Commun 211, 325-330.
4. Chee MS, Satchwell SC, Preddie E, Weston KM, &, Barrell BG, (1990) Human cytomegalovirus encodes three G protein-coupled receptor homologues. Nature 344, 774-777.
5. Alcami A, &, Saraiva M, (2009) Chemokine binding proteins encoded by pathogens. Adv Exp Med Biol 666, 167-179.
6. Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, Borlat F, Wells TN, &, Kosco-Vilbois MH, (2003) Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 100, 1885-1890.
7. Smith P, Fallon RE, Mangan NE, Walsh CM, Saraiva M, Sayers JR, McKenzie AN, Alcami A, &, Fallon PG, (2005) Schistosoma mansoni secretes a chemokine binding protein with antiinflammatory activity. J Exp Med 202, 1319-1325.
8. Deruaz M, Frauenschuh A, Alessandri AL, Dias JM, Coelho FM, Russo RC, Ferreira BR, Graham GJ, Shaw JP, Wells TN, et al,. (2008) Ticks produce highly selective chemokine binding proteins with antiinflammatory activity. J Exp Med 205, 2019-2031.
9. Frauenschuh A, Power CA, Deruaz M, Ferreira BR, Silva JS, Teixeira MM, Dias JM, Martin T, Wells TN, &, Proudfoot AE, (2007) Molecular cloning and characterization of a highly selective chemokine-binding protein from the tick Rhipicephalus sanguineus. J Biol Chem 282, 27250-27258.
10. Dias JM, Losberger C, Deruaz M, Power CA, Proudfoot AE, &, Shaw JP, (2009) Structural basis of chemokine sequestration by a tick chemokine binding protein: the crystal structure of the complex between Evasin-1 and CCL3. PLoS ONE 4, e8514.
11. Krohn S, Garin A, Gabay C, &, Proudfoot AE, (2013) The activity of CCL18 is principally mediated through interaction with glycosaminoglycans. Front Immunol 4, 193.
12. Dantas-Torres F, Figueredo LA, &, Brandao-Filho SP, (2006) Rhipicephalus sanguineus (Acari: Ixodidae), the brown dog tick, parasitizing humans in Brazil. Rev Soc Bras Med Trop 39, 64-67.
13. Palmqvist C, Wardlaw AJ, &, Bradding P, (2007) Chemokines and their receptors as potential targets for the treatment of asthma. Br J Pharmacol 151, 725-736.
14. Janeway CA, Travers P, Walport M, &, Shlomchik M, (2001) The humoral immune response. In Immunobiology: the Immune System in Health and Disease (Austin P & Lawrence E, eds). pp. 341-380. Garland Publishing, New York.
15. Stone KD, Prussin C, &, Metcalfe DD, (2010) IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 125, S73-S80.
16. Kurihara T, Warr G, Loy J, &, Bravo R, (1997) Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J Exp Med 186, 1757-1762.
17. Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV Jr, Broxmeyer HE, &, Charo IF, (1997) Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 100, 2552-2561.
18. Hajnicka V, Vancova I, Kocakova P, Slovak M, Gasperik J, Slavikova M, Hails RS, Labuda M, &, Nuttall PA, (2005) Manipulation of host cytokine network by ticks: a potential gateway for pathogen transmission. Parasitology 130, 333-342.
19. Peterkova K, Vancova I, Hajnicka V, Slovak M, Simo L, &, Nuttall PA, (2008) Immunomodulatory arsenal of nymphal ticks. Med Vet Entomol 22, 167-171.
20. Allegretti M, Cesta MC, Garin A, &, Proudfoot AE, (2012) Current status of chemokine receptor inhibitors in development. Immunol Lett 145, 68-78.
21. Schall TJ, &, Proudfoot AE, (2011) Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat Rev Immunol 11, 355-363.
22. Koelink PJ, Overbeek SA, Braber S, de Kruijf P, Folkerts G, Smit MJ, &, Kraneveld AD, (2012) Targeting chemokine receptors in chronic inflammatory diseases: an extensive review. Pharmacol Ther 133, 1-18.
23. Buatois V, Fagete S, Magistrelli G, Chatel L, Fischer N, Kosco-Vilbois MH, &, Ferlin WG, (2010) Pan-CC chemokine neutralization restricts splenocyte egress and reduces inflammation in a model of arthritis. J Immunol 185, 2544-2554.
24. White GE, McNeill E, Christou I, Channon KM, &, Greaves DR, (2011) Site-directed mutagenesis of the CC chemokine binding protein 35K-Fc reveals residues essential for activity and mutations that increase the potency of CC chemokine blockade. Mol Pharmacol 80, 328-336.
25. Proudfoot AE, &, Borlat F, (2000) Purification of recombinant chemokines from E. coli. Methods Mol Biol 138, 75-87.
26. Severin IC, Gaudry JP, Johnson Z, Kungl A, Jansma A, Gesslbauer B, Mulloy B, Power C, Proudfoot AE, &, Handel T, (2010) Characterization of the chemokine CXCL11-heparin interaction suggests two different affinities for glycosaminoglycans. J Biol Chem 285, 17713-17724.
27. Appay V, Brown A, Cribbes S, Randle E, &, Czaplewski LG, (1999) Aggregation of RANTES is responsible for its inflammatory properties. Characterization of nonaggregating, noninflammatory RANTES mutants. J Biol Chem 274, 27505-27512.